GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

CHICAGO--(BUSINESS WIRE)--Mar 31, 2025--

GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250330506353/en/

Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market 1 and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”

NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.

The Company expects this transaction to be neutral to Adjusted EPS 2 in year one and accretive thereafter.

GE HealthCare was advised by Solomon Partners Securities, LLC.

The intent to acquire the remaining 50% stake in NMP was announced in December 2024.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.

Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.

Disgruntled receiver Brandon Aiyuk called the San Francisco 49ers “stupid” and said the team is mad at him because of how much money he got in his latest contract.

Aiyuk is currently on the reserve/left squad list after he stopped showing up late last season as he rehabilitates a knee injury that has sidelined him since October 2024. He wants to be released and join a new team, but the Niners have shown no urgency to make a move even though general manager John Lynch has said he doesn't expect Aiyuk to play for the team again.

"You want to know why they really mad though? They mad because they stupid," Aiyuk said on social media on Tuesday. “They dumb. They mad they paid me $50 million in eight months and then voided my guarantees.”

Aiyuk signed a four-year, $120 million extension with San Francisco just before the start of the 2024 season following a lengthy contract “hold in” that kept him out of practice that summer.

Aiyuk played seven games and caught 25 passes that season before going down with a season-ending knee injury and the acrimony between the sides only increased. The 49ers voided $27 million guaranteed in Aiyuk's contract for 2026 last summer because he failed to participate in meetings and other team activities.

Aiyuk then left the team late in the season and has not talked to coach Kyle Shanahan or Lynch since then, communicating only through social media messages.

Aiyuk recently had an arrest warrant issued by Santa Clara County on a misdemeanor charge of exhibition of speeding in response to a video Aiyuk posted to social media last December that appeared to show him speeding on the road in front of Levi’s Stadium.

The 49ers have been waiting to see if another team is willing to trade for Aiyuk. The 49ers otherwise could either cut him or keep him on the reserve list if he fails to report to the team.

Aiyuk has three years remaining on the four-year, $120 million extension he signed last year, including a nearly $25 million option bonus due before the start of this season. But he now has no guaranteed money remaining and won't be owed anything unless he reports to the team.

The 28-year-old Aiyuk has 294 catches for 4,305 yards and 25 TDs since being drafted in the first round in 2020.

AP NFL: https://apnews.com/NFL

FILE - San Francisco 49ers wide receiver Brandon Aiyuk (11) walks of the field before an NFL football game against the Seattle Seahawks on Oct. 10, 2024 in Seattle. (AP Photo/Ben VanHouten, File)